These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37195766)

  • 1. Epidemiology and Pathogenesis of Myelodysplastic Syndrome.
    Rotter LK; Shimony S; Ling K; Chen E; Shallis RM; Zeidan AM; Stahl M
    Cancer J; 2023 May-Jun 01; 29(3):111-121. PubMed ID: 37195766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.
    Sperling AS; Gibson CJ; Ebert BL
    Nat Rev Cancer; 2017 Jan; 17(1):5-19. PubMed ID: 27834397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.
    Kennedy JA; Ebert BL
    J Clin Oncol; 2017 Mar; 35(9):968-974. PubMed ID: 28297619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
    Steensma DP
    Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia-related changes: A single institution experience.
    Gao L; Hyter S; Zhang D; Kelting S; Woodroof J; Abdallah AO; Yacoub A; McGuirk J; Abdelhakim H; Godwin AK; Cui W
    Int J Lab Hematol; 2022 Aug; 44(4):738-749. PubMed ID: 35352484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
    Nakajima H
    Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Epigenetic dysregulation in myelodysplastic syndrome].
    Sashida G; Iwama A
    Rinsho Ketsueki; 2015 Feb; 56(2):111-8. PubMed ID: 25765789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
    Ganguly BB; Banerjee D; Agarwal MB
    Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges.
    Caponetti GC; Bagg A
    Int J Lab Hematol; 2020 Dec; 42(6):671-684. PubMed ID: 32757473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice.
    DeZern AE; Malcovati L; Ebert BL
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():400-410. PubMed ID: 31099654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic and molecular pathogenesis of myelodysplastic syndromes.
    Shallis RM; Ahmad R; Zeidan AM
    Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the molecular pathophysiology of myelodysplastic syndromes.
    Bejar R; Levine R; Ebert BL
    J Clin Oncol; 2011 Feb; 29(5):504-15. PubMed ID: 21220588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
    Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
    BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetics of myelodysplastic syndromes.
    Itzykson R; Fenaux P
    Leukemia; 2014 Mar; 28(3):497-506. PubMed ID: 24247656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
    Matos A; Magalhães SMM; Rauh MJ
    Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Immune Signaling Pathways in Clonal Hematopoiesis.
    Azrakhsh NA; Mensah-Glanowska P; Sand K; Kittang AO
    Curr Med Chem; 2019; 26(28):5262-5277. PubMed ID: 30907306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
    Stankov K; Stankov S; Katanic J
    Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic predisposition to myelodysplastic syndrome and acute myeloid leukemia in children and young adults.
    Babushok DV; Bessler M; Olson TS
    Leuk Lymphoma; 2016; 57(3):520-36. PubMed ID: 26693794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications.
    Valent P
    Pathobiology; 2019; 86(1):30-38. PubMed ID: 29860246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.